期刊文献+

维持性血液透析患者成纤维细胞生长因子23影响因素探讨 被引量:2

Factors related to the higher serum fibroblast growth factor 23 in maintenance hemodialysis patients
下载PDF
导出
摘要 目的检测维持性血液透析(MHD)患者血中成纤维细胞生长因子23(FGF-23)水平,探讨血磷、血钙、甲状旁腺激素及1,25(OH)_2D_3等对FGF-23的影响。方法选择北京市海淀医院MHD患者98例,对照组肾小球过滤率正常共28例,MHD患者根据血磷水平分为低磷组、血磷达标组和高磷组,酶联免疫吸附法测定血中1,25(OH)_2D_3及FGF-23的水平,测定对照组及MHD患者血中碱性磷酸酶、钙、磷水平,同时测定MHD患者全段甲状旁腺激素。结果MHD组血清1,25(OH)_2D_3低于对照组(P<0.001),FGF- 23高于对照组(P<0.001):低磷组、血磷达标组和高磷组FGF-23水平无统计学差别(P=0.804),高磷组甲状旁腺激素明显高于低磷组及血磷达标组(P=0.001,0.010):多元回归分析显示1,25(OH)_2D_3,是MHD患者FGF-23的影响因素(r=0.481,P<0.001)。结论MHD患者血中FGF-23水平明显升高,1,25(OH) _2D_3为MHD患者FGF-23升高的影响因素,血磷不是维持性血液透析患者FGF-23升高的主要影响因素。 Objective We examined serum calcium, phosphate, intact parathyroid hormone and 1,25(OH) 2-D3 as well as serum fibroblast growth factor 23 (FGF-23), and investigated whether these factors influence serum FGF-23 in maintenance (MHD) hemodialysis patients. Methods We recruited 98 MHD patients and 28 controls with normal renal function in this study. Their serum alkaline phosphatase, calcium, phosphate and intact parathyroid hormone were determined, and their serum 1,25(OH)2-D3 and FGF-23 were measured by ELISA. We then divided the MHD patients into 3 groups: hypophosphatemia group, normal serum phosphate group and hyperphosphatemia group. Results In MHD patients, serum 1,25(OH)2-D3 was lower than that of control group (P 〈0.001), but FGF-23 was significantly higher than that of control group (P 〈0.001). Serum FGF-23 had no significant differences among hypophosphatemia group, normal serum phosphate group and hyperphosphatemia group (P = 0.804). Multiple linear regression analysis revealed that serum 1,25(OH)2-D3 was the factor that influences serum FGF-23 in MHD patients (r =0.481, P 〈0.001 ). Conclusions In MHD patients, serum FGF-23 increases significantly, and serum 1,25(OH)2-D3 is the factor relating to the increase of serum FGF-23. However, serum phosphate seems to have no impact on the increase of serum FGF-23 in MHD patients.
出处 《中国血液净化》 2008年第5期252-255,共4页 Chinese Journal of Blood Purification
关键词 血液透析 1 25(OH)2D3 成纤维细胞生长因子23 Hemodialysis 1,25(OH)2-D3 Fibroblast growth factor 23
  • 相关文献

参考文献15

  • 1Kenneth B, Jonsson. The role of fibroblast growth factor 23 in renal disease[J]. Nephrol Dial Transplant, 2005, 20: 479-482.
  • 2Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency Jn chronic kidney disease[J]. J Am Soc Nephrol, 2005,16:2205-2215.
  • 3Collins MT, Lindsay JR, Jain A, et al. Fibroblast growth factor-23 is regulated by lalpha, 25-dihydroxyvitamin D [J]. J Bone Miner Res, 2005,20:1944-1950.
  • 4Fukagawa M, Kazama JJ. FGF23: its role in renal bone disease[J]. Pediatr Nephrol, 2006,21:1802-1806.
  • 5Westerberg PA, Linde T, Wikstrom B, et al. Regulation of fibroblast growth factor-23 in chronic kidney disease [J]. Nephrol Dial Transplant, 2007,22:3202-3207.
  • 6Tortes PU, Friedlander G, MC de Vernejoul et al. Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients[J].Kidney Int, 2008, 73:102- 107.
  • 7Nishi H, Nii-Kono T, Nakanishi S, et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism[J]. Nephron Clin Praet, 2005, 101: c94-c99.
  • 8陈旻译.血清磷水平的评价.王海燕,王梅主译,慢性肾脏病及透析的临床实践指南Ⅱ[M].第一版.北京,人民卫生出版社,2005,347-349.
  • 9Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF- 23 levels predict the efficacy of calcitriol therapy in dialysis patients[J]. Kidney Int, 2005, 67: 1120-1125.
  • 10Fliser D, Kollerits B, Neyer U, et al. Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study [J]. J Am Soc Nephrol, 2007,18: 2600-2608.

二级参考文献12

  • 1Quarles LD,Sherrard DJ,Adler S, et al. The calcimimetics AMG073 as a potential treatment for secondary hyperparathyroidism of end - stage re nal disease. J Am Soc Nephrol, 2003,14(3 ): 575 - 83
  • 2Lindberg JS,MoeSM, GoodmanWG, etal. ThecalcimimeticAMG073 reduces parathyroid hormon and calcium x phosphorous product in secondary hyperparathyroidism. Kidney Int,2003,63 ( 1 ) :248 - 54
  • 3Silver J, Kilav R, Naveh - Many T. Mechanisms of secondary hyper parathyroidism. Am J Physiol Renal Physiol, 2002,283: F367 - F376
  • 4Ganesh SK, Stack AG, Lewin NW, et al. Association of elevated serum PO( 4), CaXPO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients L Am J Soc Nephrol, 2001,12:2131 - 2138
  • 5Locatelli F. The need for better control of secondary hyperparathyroidism. Nephrol Dial Transplant, 2004, 19 Suppl 5:v15 - v19
  • 6National Kidney Foundation. Kidney Disease Qality Outcomes Initiative (K/DOQI) clinical prictice guidlines. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003, 42 ( Suppl 3): S1 - S20
  • 7Goodman. W G. Recent developments in the management of secondary hyperparathyroidism. Kidney Int,2001,59:1187 - 1201
  • 8Goodman WG. Calcimimetic agents and secondary hyperparathyroidism: rationale for using results from clinical trials. Pediatr Nephrol, 2003, 18 (12): 1206 - 10
  • 9Torres P U. Clinical experience with cinacalcet HCL. Nephrol Dial Transplant, 2004, 19[Suppl 5]: v27 - v33
  • 10Wada M, Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant, 2003, Suppl 3:12

共引文献3

同被引文献38

  • 1Drueke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failuref[J].J Am Soc Nephrol, 2000, 11:1141-1152.
  • 2Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling[J]. Physiol Rev ,2001, 81:239-297.
  • 3Henley C, Davis J, Miller G, et al. Calcium gluconate increases iCa, attenuates pPTH and parathyroid (PT) hyperplasia in uremic rats without causing calcification:Ab stract 162 presented at National Kidney Foundation Spring Clinical Meeting, 19-23 April 2006: Chicago.
  • 4Roussanne MC, Lieberherr M, Souberbielle JC, et al. Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate[J]. Eur J Clin Invest, 2001, 31:610-616.
  • 5D'Souza-Li L, Yang B, Canaff L, et al. Identification and functional characterization of novel calcium sensing re ceptor mutations in familial hypocalciuric hypcrcalcemia and autosomal dominant hypocalcemia[J]. J Clin Endocrinol Metab. 2002. 87:1309?318.
  • 6Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of pa tients with hyperparathyroidism[J]. Kidney Int, 1997, 51: 328-336.
  • 7Nemeth EF, Heaton Wll, Miller M, et al. Pharmacoldynamics of the type Ⅱ calcimimetic compound cinacalcet HCI[J].J Pharmacol Exp Ther, 2004, 308:627- 635.
  • 8Goodman WG, Frazao JM, Goodkin DA, et al. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism[J]. Kidney Int,2000, 58:436-445.
  • 9Levi R, Ben Dov IZ, Lavi-Moshayoff V, et al. Increased parathyroid hormone gene expression in seeondacy hyperparathyroidism of experimental uremia is reversed by fication of the trans acting factoc AUF1[J].J Am Soc Nephrol ,2006, 17:107-112.
  • 10Colloton M,Shatzen E,Miller G,et al.Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism[J].Kidney Int,2005, 67:467-476.

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部